Study reveals aggressive EGFR mutation impacting lung adenocarcinoma, suggesting tailored therapeutic strategies.
Our study reveals the rare EGFR L833V/H835L cis mutation as an aggressive oncogenic driver in lung adenocarcinoma, highly responsive to EGFR-directed therapy. These findings provide crucial therapeutic strategies for patients with this specific EGFR variant, addressing a current gap in precision medicine.
No takes yet. Share an insight, caveat, or question.
Jeon et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: